← 홈

폐암 (NSCLC)

150개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 150개
AntibodystaleCorvus Pharmaceuticals, Inc.Phase 1

pembrolizumab (Keytruda, CPI-006 + pembrolizumab)

Non-Small Cell Lung Cancer; Renal Cell Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleIdris BahceApproved

durvalumab (Imfinzi, Consolidation durvalumab)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Docetaxel/Carboplatin/Bevacizumab/Erlotinib (Docetaxel/Carboplatin/Bevacizumab/Erlotinib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + Monalizumab)

Stage III Non-small Cell Lung Cancer; Unresectable · Stage III Non-small Cell Lung Cancer

#StageIIINon-smallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 23.9%임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + Oleclumab)

Stage III Non-small Cell Lung Cancer; Unresectable · Stage III Non-small Cell Lung Cancer

#StageIIINon-smallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 23.9%임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab plus radiotherapy)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleGuangdong Provincial People's H…Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, Envafolimab injections+intravenous Disitamab Vedotin+carboplatin)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-DCs (EphA2-targeted CAR-DCs)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-T Cells (EphA2-targeted CAR-T Cells)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Center, KoreaPhase 2

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

EGFR Positive Non-small Cell Lung Cancer · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
ADCBiologicstaleImmunome, Inc.Phase 1

IM-1617 (IM-1617)

Colorectal Cancer; Non-Small Cell Lung Cancer · Colorectal Cancer

#ColorectalCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleUniversity of ChicagoPhase 2

for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab (Investigator Choice Immunotherapy, Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab))

Non-Small Cell Lung Cancer; Metastatic Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAline Fusco Fares, MDPhase 2

nivolumab (Opdivo, Low-dose nivolumab combined with platinum-based doublet chemotherapy)

Lung Cancer, Nonsmall Cell; Non-Small Cell Lung Cancer NSCLC · Lung Cancer, Nonsmall Cell

#LungCancerNonsmallCell#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 40.3%임상시험 1상태 ACTIVE
AntibodystaleAssistance Publique Hopitaux De…Phase 2

IPH2201 (Monalizumab, Monalizumab (IPH2201))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING

5 / 8 페이지

← 이전다음 →